23 February 2022
A summary of the commitments and targets within the United Nations General Assembly’s 2021 Political Declaration on HIV and AIDS.The United Nations General Assembly’s 2021 Political Declaration on AIDS features bold global commitments and targets for 2025 that are ambitious but... achievable if countries and communities follow the evidence-informed guidance within the Global AIDS Strategy 2021–2026. This UNAIDS publication provides a summary of those commitments and targets to get every country and every community on-track to end AIDS as a public health threat by 2030
more
The study on single-dose cholera vaccine in Zambia evaluates the effectiveness of using a single dose of the oral cholera vaccine (OCV) during a 2016 outbreak in Lusaka. Due to limited vaccine supply, authorities opted for a one-dose emergency campaign instead of the usual two-dose regimen. A matche...d case-control study was conducted to assess vaccine effectiveness, showing 88.9% short-term protection against cholera. The findings suggest that a single-dose approach can be an effective strategy in outbreak settings, especially when vaccine supplies are constrained. However, further research is needed to determine long-term immunity and effectiveness in young children.
more
Oxford Policy Management (OPM) - APW with UNAIDS (thru TSF)
Series on Disability-Inclusive Development. This publication introduces the key concepts for disability-inclusive development and highlights practical examples by CBM, to contribute to the dialogue on disability-inclusive development
This toolkit is designed as a resource for CBM that can be used in a variety of ways: to support staff induction, team meetings, refresher days and training workshops. It can also be used as a tool for personal reflection and self-study. Tips for those intending to use it as a training resource are ...shaded differently.
more
The report surveyed 9 leading bilateral and multilateral education donors in respect of their approach to disability-inclusive education.
Strengthening Community responses to HIv Treatment and Prevention
A Guide For Multicentre Trials in High-Burden Countries
Biennial Report. SUBMITTED TO THE UNITED NATIONS GENERAL ASSEMBLY SPECIAL SESSION ON HIV AND AIDS
Reporting period: January 2012 – December 2013
The Mapping Antimicrobial Resistance and Antimicrobial Use Partnership (MAAP) project has conducted a multi-year, multi-country study that provides stark insights on the under-reported depth of the antimicrobial resistance (AMR) crisis across Africa and lays out urgent policy recommendations to addr...ess the emergency.
MAAP reviewed 819,584 AMR records from 2016-2019, from 205 laboratories across Burkina Faso, Cameroon, Eswatini, Gabon, Ghana, Kenya, Malawi, Nigeria, Senegal, Sierra Leone, Tanzania, Uganda, Zambia, and Zimbabwe. MAAP also reviewed data from 327 hospital and community pharmacies and 16 national-level AMC datasets.
more
Atherosclerotic lower-extremity peripheral artery disease (PAD) is increasingly recognized as an important cause of cardiovascular morbidity and mortality that affects more than 230 million people worldwide. Traditional cardiovascular risk factors, including advanced age, smoking, and diabetes, are ...strongly linked to an increase risk of PAD. Although PAD has been historically underappreciated compared to coronary artery disease and stroke, greater attention on PAD in recent years has led to important new epidemiologic insights in the areas of thrombosis, inflammation, dyslipidemia, and microvascular disease. In addition, the concept of polyvascular disease, or clinically-evident atherosclerosis in multiple arterial beds, is increasingly identified as a particularly malignant cardiovascular disease worthy of special clinical attention and further study. It is noteworthy that PAD may increase the risk of adverse outcomes in similar or even greater magnitude than coronary disease or stroke. In this review, we highlight important new advances in the epidemiology of PAD with a particular focus on polyvascular disease, emerging biomarkers, and differential risk pathways for PAD compared to other atherosclerotic diseases.
more